Clinical Cancer Research, 1078-0432

Journal

Related Publications
  1. Hypoxic activation of the PERK/eIF2α arm of the unfolded protein response promotes metastasis through induction of LAMP3

    Mujcic, H., Nagelkerke, A., Rouschop, K. M. A., Chung, S., Chaudary, N., Span, P. N., Clarke, B., Milosevic, M., Sykes, J., Hill, R. P., Koritzinsky, M. & Wouters, B. G., 15-Nov-2013, In : Clinical Cancer Research. 19, 22, p. 6126-6137 12 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  2. Interferon-Stimulated Genes Are Involved in Cross-resistance to Radiotherapy in Tamoxifen-Resistant Breast Cancer

    Post, A. E. M., Smid, M., Nagelkerke, A., Martens, J. W. M., Bussink, J., Sweep, F. C. G. J. & Span, P. N., 15-Jul-2018, In : Clinical Cancer Research. 24, 14, p. 3397-3408 12 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  3. Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT)

    Task Force Methodology Dev, 1-Jun-2020, In : Clinical Cancer Research. 26, 11, p. 2461-2465 5 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  4. Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma

    Krämer, P., Talhouk, A., Brett, M. A., Chiu, D. S., Cairns, E. S., Scheunhage, D. A., Hammond, R. F., Farnell, D., Nazeran, T. M., Grube, M., Xia, Z., Senz, J., Leung, S., Feil, L., Pasternak, J., Dixon, K., Hartkopf, A., Krämer, B., Brucker, S., Heitz, F., du Bois, A., Harter, P., Kommoss, F., Sinn, H-P., Heublein, S., Kommoss, F., Vollert, H-W., Manchanda, R., de Kroon, C. D., Nijman, H. W., de Bruyn, M., Thompson, E. F., Bashashati, A., McAlpine, J. N., Singh, N., Tinker, A. V., Staebler, A., Bosse, T., Kommoss, S., Köbel, M. & Anglesio, M. S., Nov-2020, In : Clinical Cancer Research. 83, 5, p. 1503 12 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  5. Low-dose metformin reprograms the tumor immune microenvironment in human esophageal cancer: Results of a phase II clinical trial

    Wang, S., Lin, Y., Xiong, X., Wang, L., Guo, Y., Chen, Y., Chen, S., Wang, G., Lin, P., Chen, H., Yeung, S-C. J., Bremer, E. & Zhang, H., 15-Sep-2020, In : Clinical Cancer Research. 26, 18, p. 4921-4932 12 p.

    Research output: Contribution to journalArticleAcademicpeer-review

View all (117) »

ID: 1461357